Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.
企業コードMOBI
会社名Mobia Medical Inc
上場日May 08, 2026
最高経営責任者「CEO」Foust (Richard John)
従業員数- -
証券種類Ordinary Share
決算期末- -
本社所在地2802 Flintrock Trace, Suite 226
都市
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号78738
電話番号
ウェブサイト
企業コードMOBI
上場日May 08, 2026
最高経営責任者「CEO」Foust (Richard John)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし